SEATTLE, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision

- Initiated a Phase 1 trial of Icosavax’s first combination bivalent vaccine candidate, IVX-A12, against respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) in older adults - - IVX-A12 is the first bivalent vaccine candidate against both RSV and hMPV to reach clinical stage

SEATTLE, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision

- IVX-A12 is the first combination bivalent vaccine candidate against both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) to reach clinical stage - - Phase 1 topline interim results expected in mid-2023 - - Phase 2 initiation planned to follow in 2H 2023 - SEATTLE, Oct.

– Announced positive topline interim Phase 1/1b results for VLP vaccine candidate IVX-121 against respiratory syncytial virus (RSV) - – Icosavax plans to file an IND and initiate a Phase 1 trial for IVX-A12, a combination bivalent RSV + human metapneumovirus (hMPV) VLP candidate, in 2H 2022 - –

- Antigen component of IVX-411 found to be unstable; issue specific to molecule, with no evidence of read-through to other Icosavax programs - - Now focused on a bivalent strategy for COVID-19 candidate development displaying computationally engineered RBD antigens; provides optionality as a

SEATTLE, July 06, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision

- IVX-121 demonstrated robust immunologic response to RSV, with comparable Geometric Mean Titer (GMT) levels achieved at Day 28 in both young and older adult groups - - IVX-121 was generally well tolerated with no vaccine-related SAEs - - Provides initial indication of a differentiated VLP platform

SEATTLE, June 01, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle platform technology to develop combination vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a

- Enrollment completed in older adults portion of Phase 1/1b trial of IVX-121, a virus like particle (VLP) vaccine candidate displaying the prefusion stabilized Respiratory Syncytial Virus (RSV) F antigen - - Topline, interim Phase 1/1b data for IVX-121 in RSV, including younger and older adults,